Related Experiment Videos
Thiazolidinedione induced thyroid associated orbitopathy
Seongmu Lee1, Angelo Tsirbas, Robert A Goldberg
1Division of Orbital and Ophthalmic Plastic and Reconstructive Surgery, Jules Stein Eye Institute, and the Department of Ophthalmology, David Geffen School of Medicine at UCLA, Los Angeles, California, USA. seongmu.lee@ucla.edu
Thiazolidinediones may worsen thyroid-associated orbitopathy (TAO) in patients with Graves' disease. Discontinuation of these drugs can lead to disease stabilization and vision improvement.
Area of Science:
- Endocrinology
- Ophthalmology
Background:
- Thyroid-associated orbitopathy (TAO) is an autoimmune condition affecting the eyes.
- Thiazolidinediones (TZDs) are a class of antidiabetic drugs.
Observation:
- A patient with a history of Graves' disease and stable TAO experienced rapid TAO progression after starting TZDs for glycemic control.
- Ophthalmic findings indicated a significant worsening of TAO.
Findings:
- Discontinuation of TZDs resulted in disease stabilization.
- Patient's vision normalized after TZD withdrawal.
Implications:
- TZDs may exacerbate TAO, necessitating careful consideration in diabetic patients with autoimmune thyroid disorders.
- Clinicians should monitor for TAO exacerbation when prescribing TZDs to at-risk patients.
Related Concept Videos
Oral Hypoglycemic Agents: Biguanides and Glitazones
Graves' Disease I: Introduction
Graves Disease II: Pathophysiology
Hyperthyroidism I: Introduction
Hyperthyroidism II: Pathophysiology
Antihypertensive Drugs: Thiazide-Class Diuretics